{"schema_version":"secwatch.filing_event.v1","accession":"0001034842-26-000005","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.431973+00:00","generated_at":"2026-05-16T10:46:03.774987+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Rigel Pharmaceuticals Provides Preliminary Q4 2025 Revenue of $69.8M and 2026 Outlook of $275-290M","bullets":["Preliminary Q4 2025 total revenue $69.8M, net product sales $65.4M, vs $57.6M and $46.5M in Q4 2024.","Full year 2025 total revenue $294.3M, net product sales $232.0M, up 60% from 2024.","2026 outlook: total revenue $275-290M, net product sales $255-265M, positive net income expected.","R289 Phase 1b study: RBC-TI achieved by 33% (6/18) evaluable patients at doses ≥500 mg QD; enrollment on track for RP2D selection H2 2026.","FDA approved boxed warning for GAVRETO (pralsetinib) for serious infections; postmarketing commitment met."],"urls":{"canonical":"https://secwatch.observer/filing/0001034842-26-000005","json":"https://secwatch.observer/filing/0001034842-26-000005.json","markdown":"https://secwatch.observer/filing/0001034842-26-000005.md","text":"https://secwatch.observer/filing/0001034842-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000005/0001034842-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000005/rigl-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T10:46:03.774987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}